News about regulatory momentum for an off-the-shelf cell therapy for Parkinson’s, previewing a piece on its clinical and manufacturing implications.
Key Takeaways
- FDA accelerates development of XellSmart’s off-the-shelf Parkinson’s therapy
- XS411 has already received permission to enter clinical trials in both China and the United States
- They can improve symptoms, sometimes dramatically, but they cannot replace the cells that have already been lost